IL6 and COVID-19: In COVID-19 cases, MSCs are able to increase the lymphocyte count and regulatory DCs to raise their antiviral characteristic which results in the decreased level of C-reactive protein and pro-inflammatory cytokines (IL-6, TNFα, IL-8, and so on) that are the main markers of inflammation and ROS to diminish the inflammation and oxidative stress [58].